Skip to main content
. Author manuscript; available in PMC: 2018 Feb 9.
Published in final edited form as: Clin Cancer Res. 2009 Mar 10;15(6):2130–2139. doi: 10.1158/1078-0432.CCR-08-2632

Figure 2. CD4 T cell responses against NY-ESO-1 representative peptides by IFN-γ ELISPOT.

Figure 2

Figure 2

Results shown throughout vaccination (from pre-vaccine [Pre] to week [wk] 13) following pre-sensitization, and represented as the number of spots for 50,000 CD4 T cells against targets pulsed with NY-ESO-1 peptides (with median number of spots for irrelevant control target <10 spots). Results representative of at least two repeat assays. NY-ESO-1 specific CD4 T cell responses measured throughout the clinical trial in (A) 10 prostate cancer patients and (B) 5 NSCLC patients and 1 esophageal cancer patient, demonstrating inconsistent T cell responses with intra- and inter-patient variability.